ADAM CRANER: Open Payments
NPI 1952326357 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$920 in 55 payments from 17 companies in 2025. Trend: 2023 $1,514 · 2024 $1,682 · 2025 $920
Food & beverage: $920
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $297 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $114 |
| Exact Sciences Corporation | 4 | $70 |
| Novo Nordisk Inc | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 4 | $59 |
| Lilly USA, LLC | 3 | $55 |
| SANOFI-AVENTIS U.S. LLC | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Janssen Biotech, Inc. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Cologuard Collection Kit, MOUNJARO, TZIELD, Wegovy, TREMFYA.
Industry payments across UT — which companies pay providers there.
